Also considered
27 papers judged, 3 emailed · Read the digest →
Updated phase III RCT (AEGEAN) in resectable NSCLC, published in JCO, reporting continued event-free survival benefit and numerical improvements in disease-free and overall survival with perioperative durvalumab plus neoadjuvant chemotherapy. Supports durvalumab as a standard perioperative option in resectable NSCLC.
Phase 1-2 dose-escalation/expansion trial in previously treated RAS-mutant NSCLC, published in NEJM, evaluating the novel pan-RAS(ON) inhibitor daraxonrasib; establishes safety and preliminary efficacy signal for a first-in-class agent targeting a previously undruggable driver mutation.
Retrospective real-world cohort study using a US clinico-genomic database in advanced EGFR-mutant NSCLC treated with front-line osimertinib, published in Lung Cancer. Shows that L858R mutation and TP53 co-mutation are independent prognostic markers of worse survival, potentially useful for risk-stratifying patients but not changing treatment selection.
Narrative review in J Thorac Oncol summarizing two decades of immunotherapy development across lung cancer stages; provides a state-of-the-art overview of clinical integration, limitations, and future directions to contextualize current practice.
Large real-world database analysis in JNCI of over 6,600 advanced NSCLC patients examining how often genomic profiling results translated into guideline-concordant targeted therapy use. Highlights substantial underuse of approved and off-label matched therapies, informing efforts to improve biomarker-driven treatment implementation.
Retrospective multi-cohort translational study in EGFR-mutant lung adenocarcinoma, published in Journal of Thoracic Oncology. DNA/RNA variant allele fraction-based risk stratification predicted relapse and informed benefit from adjuvant/timing of EGFR TKI therapy, with validation in an independent cohort.
News report in Cancer Discovery on a phase 1 trial of the pan-RAS inhibitor daraxonrasib showing tumor shrinkage in a meaningful proportion of previously treated RAS-mutant NSCLC patients. Signals a promising new targeted therapy class already approved in pancreatic cancer, with a phase 3 lung trial now underway.
Large real-world registry analysis (ESME database, France) of treatment patterns and outcomes in advanced/metastatic NSCLC and SCLC, published in Lung Cancer. Documents the shift to immunotherapy-based first-line treatment and provides contemporary survival benchmarks to contextualize clinical practice.
Narrative review on large cell neuroendocrine carcinoma of the lung, published in Lung Cancer, summarizing diagnostic, molecular, and multimodality management approaches. Provides an updated framework that could inform classification and treatment decisions for this rare, aggressive subtype.
Retrospective multicenter cohort study in Lung Cancer of ALK-rearranged NSCLC patients treated with first-line next-generation ALK TKIs, examining whether multiple ALK fusion isoforms affect outcomes. Found that isoform multiplicity is independently associated with shorter progression-free survival, suggesting a potential biomarker for resistance to next-generation ALK inhibitors.
Multicenter retrospective cohort study in Lung Cancer examining outcomes of adding immunotherapy to chemotherapy after SCLC transformation in EGFR-mutant NSCLC. Suggests a potential survival benefit with immunotherapy addition, though based on small numbers, offering a practice-informing signal for this rare resistance scenario.
Prespecified patient-reported outcomes analysis from the phase 3 DeLLphi-304 trial in extensive-stage SCLC after platinum-based chemotherapy, published in Lung Cancer. Shows tarlatamab improves symptom burden and quality of life versus standard chemotherapy, supporting its tolerability profile alongside prior efficacy data.
Retrospective multicenter study in osimertinib-treated EGFR exon 19 deletion NSCLC, published in Lung Cancer. Identifies specific deletion subtypes (e.g., L747\_A750delinsP) associated with markedly worse PFS/OS, suggesting a need for subtype-aware prognostication.
Preclinical/translational study combining patient tumor samples and mouse models, published in J Immunother Cancer, identifying a PD-L1-driven metabolic pathway (PDK4/GLS) associated with anti-PD-1 resistance in NSCLC and showing that targeting this axis restores immunotherapy efficacy in mouse models. Suggests a potential combination strategy to overcome checkpoint-inhibitor resistance, pending clinical validation.
Systematic review and meta-analysis pooling pulmonary adverse event rates for antibody-drug conjugates in SCLC and NSCLC, published in J Thorac Oncol. Quantifies pneumonitis/ILD incidence and severity, informing monitoring and risk stratification when using ADCs in lung cancer.
Multicenter diagnostic accuracy study in Lung Cancer evaluating an AI tool for detecting and classifying thoracic lymph nodes on CT versus histopathology in operable thoracic malignancies. Could improve nodal staging accuracy but does not address systemic therapy selection directly.
Single-arm phase 2 trial in checkpoint-inhibitor-naive NSCLC patients combining a MUC1 vaccine with nivolumab, published in Oncoimmunology. The trial closed early for slow accrual and showed limited overall benefit, though one exceptional responder highlighted potential biomarkers of vaccine-driven immune activity.
Preclinical and translational study in Cancer Discovery identifying tumor-secreted ADAMTSL4 as a driver of cancer cachexia via TGFβ activation, with correlative data in colorectal and lung cancer patients. Suggests a potential future therapeutic target for cachexia but does not inform any current anticancer treatment decision.
Preclinical/mechanistic study in NSCLC, published in Lung Cancer, identifying IL20RB as a driver of JAK2-STAT3 signaling that promotes tumor growth and immune evasion, with a repurposed drug shown to synergize with anti-PD-L1 in vitro; largely prognostic/mechanistic without clinical validation.
Retrospective translational analysis in Cancer Discovery examining lymphoid aggregates in melanoma and lung adenocarcinoma brain metastases and their prognostic association. Findings are prognostic rather than predictive of a specific therapy, informing understanding of intracranial immune biology but not yet changing treatment selection.
Population-based 33-year cohort study from Türkiye, published in Lung Cancer, quantifying lung cancer and mesothelioma mortality burden from environmental asbestos exposure; informs epidemiologic risk awareness but has no direct treatment implication.
Single-arm phase 2 trial of first-line pyrotinib plus apatinib in treatment-naive HER2-mutant/amplified advanced NSCLC, published in Lung Cancer. Shows promising response rates and PFS versus a propensity-matched chemotherapy comparator, suggesting a potential targeted first-line option pending randomized confirmation.
Translational analysis in Lung Cancer of tumor samples from a randomized trial comparing radiotherapy doses in limited-stage SCLC, identifying molecular subtypes associated with differential chemoradiotherapy outcomes. Exploratory prognostic biomarker finding rather than one guiding a specific treatment selection change.
Retrospective multicenter cohort study of resectable NSCLC patients undergoing neoadjuvant chemo-immunotherapy, published in Lung Cancer, examining prognostic value of nodal downstaging; finds ypN0 status (regardless of baseline nodal stage) predicts favorable outcomes while ypN+ predicts recurrence, and adjuvant immunotherapy did not add benefit in ypN0 patients.
Case-based practical discussion in Lung Cancer summarizing strategies for managing inoperable stage III NSCLC patients ineligible for standard chemoradiotherapy plus durvalumab due to frailty or comorbidities. Offers pragmatic guidance for a common but trial-underrepresented population, informing individualized treatment decisions.
Retrospective cohort study in resected invasive lung adenocarcinoma, published in Journal of Thoracic Oncology, proposing a lymph node pathologic grading system that independently predicts recurrence-free survival and may refine N-staging, though it is prognostic rather than therapy-predictive.
Multicenter retrospective study using AI-based quantification of tumor bed stroma after neoadjuvant therapy (immunotherapy, TKI, or chemotherapy) in advanced NSCLC, published in Lung Cancer. Finds immunotherapy associated with more favorable pathologic regression and a distinct immune-reactive tumor microenvironment, offering exploratory insight into response biology rather than an actionable predictive marker.